查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1950496

长效生长抑制素类似物市场：按产品类型、适应症、给药途径、通路、病患年龄层分類的全球预测（2026-2032年）

Long-acting Somatostatin Analogues Market by Product Type, Indication, Route Of Administration, Distribution Channel, Patient Age Group - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 182 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2025 年，长效生长抑制素类似物市场规模将达到 36.5 亿美元，到 2026 年将达到 40.6 亿美元，到 2032 年将达到 78.5 亿美元，复合年增长率为 11.55%。

关键市场统计数据
基准年 2025 36.5亿美元
预计年份：2026年 40.6亿美元
预测年份 2032 78.5亿美元
复合年增长率 (%) 11.55%

策略性应用：将长效生长抑制素类似物定位为不断发展的慢性内分泌和神经内分泌疾病治疗路径的核心要素

长效生长抑制素类似物的治疗领域已从一种小众治疗选择转变为慢性内分泌和神经内分泌疾病管理的核心组成部分。过去十年，临床医生和医疗保健系统越来越依赖缓释製剂来提高患者依从性、减少给药频率，并稳定需要持续荷尔蒙抑制的疾病的生化指标。随着临床实务的发展，人们对患者便利性、疗效评估和整合式诊疗路径的期望也随之提高。

不断发展的临床实践、製剂创新和综合患者服务如何重塑生长抑制素疗法的开发和商业化

长效生长抑制素类似物的市场环境正经历着一场变革，其驱动力来自临床实践的改变、产品创新以及医疗保健期望的转变。临床医生日益关注治疗的连续性和患者报告的疗效，这使得给药间隔、注射耐受性和可预测的动态变得尤为重要。同时，生产商也积极推行生命週期策略，致力于改善製剂、开发新型给药装置并扩大适应症，以确保药物持续的治疗价值。

评估2025年美国关税变化对供应链、筹资策略和治疗获取动态的系统性影响

贸易和关税政策的变化会对治疗方法的生产、定价和供应产生重大的下游影响。 2025年美国关税政策迫使供应链相关人员重新评估其筹资策略，尤其是那些拥有跨境生产设施的高价值活性药物原料药和成品药生产商。为因应这项变化，生产商已实现供应商多元化，加快了生产回流，并与贸易条件有利地区的委託製造合作，以减轻关税波动的影响。

详细的細項分析揭示了产品类型、适应症细微差别、给药途径、通路和年龄组如何驱动差异化的策略重点。

细緻的细分框架阐明了临床需求和供应模式的差异如何影响产品策略和商业化重点。产品类型维度突显了Lanreotide缓释凝胶、Octreotide长效製剂和Pasireotide肽长效製剂的独特治疗属性，其製剂特性和给药途径会影响临床医师的偏好和给药流程。基于适应症的区分突显了肢端肥大症、库欣氏症和神经内分泌肿瘤（NETs）的不同使用模式。神经内分泌肿瘤进一步细分为胃肠胰神经内分泌肿瘤（NETs）和肺神经内分泌肿瘤（NETs），每种肿瘤都有其自身的诊断路径和多学科治疗需求。

美洲、欧洲、中东和非洲以及亚太地区的区域背景和市场准入因素将影响临床应用和分销策略。

区域趋势在全球范围内影响医疗服务取得、临床实践规范和医疗服务提供者策略。在美洲，我们持续看到专科中心与大型医院系统之间密切合作，这影响着竞标行为、药品分销物流和病患支援服务。在这些市场，支付方和医疗服务提供者之间的协作在製定药品目录和确保复杂慢性病患者的医疗服务取得方面发挥核心作用。

药物研发公司、专业製造商和服务合作伙伴之间的竞争与合作趋势将决定生长抑制素类似物市场的长期定位。

此领域的竞争格局由成熟的原厂药厂、专业生产商和支持製剂及给药方式创新的合约研发机构 (CDO) 共同构成。主要企业采取了多元化策略，将投资范围扩展至生命週期管理、适应症拓展和病患服务，以增强产品差异化。与临床网络和关键意见领袖 (KOL) 的合作仍然是推动指南采纳和建立真实世界证据计画（以证明药物的长期安全性和耐受性）的关键所在。

为领导者提供切实可行的建议，以整合製剂创新、供应链韧性和支付方合作，从而改善临床应用和长期可及性。

产业领导者应优先考虑将临床差异化、营运韧性和支付方价值主张结合的策略。首先，投资于改进的製剂和给药技术，以减轻给药负担并提高耐受性，将有助于增强临床医生的偏好和患者的依从性。这些改进应辅以强有力的真实世界证据项目，以证明其临床和人体疗效。其次，生产和筹资策略多元化将降低贸易中断风险，并实现更可预测的供应。同时，与区域契约製造组织 (CMO) 建立策略合作伙伴关係可以加速本地市场准入和产能扩张。

采用透明的多方法研究途径（临床医师参与、监管审查、供应链分析）可以得出可靠、可操作的结论。

本调查方法结合了定性初步研究和定量检验，以确保证据基础的全面性和可靠性。初步研究包括对内分泌科医生、神经内分泌肿瘤科医生、医院药剂师、采购人员和支付方代表的访谈，以了解临床实践、报销趋势和分销挑战等方面的真实观点。此外，也邀请由临床专家组成的顾问小组对这些调查进行补充，以检验真实世界的治疗路径和对未满足需求的解释。

对临床机会、营运需求和策略重点的综合分析揭示了生长抑制素治疗中持续创造价值的驱动因素

累积分析表明，在临床上对持续生化指标控制的需求以及对以患者为中心的医疗服务日益增长的期望的推动下，长效生长抑制素类似物在慢性内分泌和神经内分泌疾病的治疗中正发挥着越来越重要的战略作用。製剂和给药方式的创新，结合强化的病人支持服务，为提高病人的用药依从性和就医体验提供了切实的机会。此外，受区域报销复杂性、供应链脆弱性和支付方审查等因素影响的更广泛的商业环境，要求生产商采取将临床差异化与营运韧性相结合的综合策略。

目录

第一章：序言

第二章调查方法

  • 研究设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查前提
  • 调查限制

第三章执行摘要

  • 首席主管观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 上市策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会地图
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

8. 长效生长抑制素类似物市场（依产品类型划分）

  • Lanreotide缓释凝胶
  • OctreotideLAR
  • PasireotideLAR

9. 依适应症分類的长效生长抑制素类似物市场

  • 肢端肥大症
  • 库欣氏症
  • 神经内分泌肿瘤
    • 胃肠胰神经内分泌肿瘤
    • 肺神经内分泌肿瘤

10. 依给药途径分類的长效生长抑制素类似物市场

  • 深层皮下注射
  • 肌肉内注射

11. 长效生长抑制素类似物市场（依分销通路划分）

  • 医院药房
  • 邮购药房
  • 零售药房

12. 依患者年龄组别分類的长效生长抑制素类似物市场

  • 成人版
  • 儿童

13. 各地区长效生长抑制素类似物市场

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

14. 长效生长抑制素类似物市场（依组别划分）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

15. 各国长效生长抑制素类似物市场

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

16. 美国长效生长抑制素类似物市场

17. 中国长效生长抑制素类似物市场

第十八章 竞争格局

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • Amneal Pharmaceuticals, Inc.
  • Bachem Holding AG
  • BioSynthema Inc.
  • Camurus AB
  • Chengdu Tiantaishan Pharmaceutical Co., Ltd.
  • Chiasma, Inc.
  • Cipla Limited
  • Crinetics Pharmaceuticals, Inc.
  • Dauntless Pharmaceuticals, Inc.
  • Debiopharm Group
  • EVER Pharma GmbH
  • Ferring Pharmaceuticals
  • Ipsen Pharma
  • Midatech Pharma PLC
  • Mylan NV
  • Novartis AG
  • Peptron Inc.
  • Pfizer Inc.
  • Recordati SpA
  • Sandoz International GmbH
  • ScinoPharm Taiwan Ltd.
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • Wockhardt Ltd.
  • Zydus Lifesciences Limited
Product Code: MRR-4F7A6D4FD89F

The Long-acting Somatostatin Analogues Market was valued at USD 3.65 billion in 2025 and is projected to grow to USD 4.06 billion in 2026, with a CAGR of 11.55%, reaching USD 7.85 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 3.65 billion
Estimated Year [2026] USD 4.06 billion
Forecast Year [2032] USD 7.85 billion
CAGR (%) 11.55%

A strategic introduction framing long-acting somatostatin analogues as central elements of evolving chronic endocrine and neuroendocrine care pathways

The therapeutic class of long-acting somatostatin analogues has shifted from niche treatment options to central components of chronic endocrine and neuroendocrine disease management. Over the last decade, clinicians and healthcare systems have increasingly relied on extended-release formulations to improve adherence, reduce administration frequency, and stabilize biochemical control in conditions that require sustained suppression of hormone activity. As clinical practice evolves, so do expectations around patient convenience, outcomes measurement, and integrated care pathways.

Consequently, stakeholders across the value chain-clinicians, payers, distributors, and manufacturers-are re-evaluating product positioning and service models. Regulatory authorities have emphasized safety monitoring and post-approval evidence generation, prompting manufacturers to expand real-world evidence programs and patient support services. In parallel, technological refinements in formulation and delivery have created opportunities to reduce variability in therapeutic effect and to differentiate products through improved tolerability and administration experience. These dynamics create a complex environment where strategic clarity and operational agility determine the pace at which new and existing therapies deliver sustained clinical and commercial value.

How clinical practice evolution, formulation innovation, and integrated patient services are reshaping the development and commercialization of somatostatin therapies

The landscape for long-acting somatostatin analogues is undergoing transformative shifts driven by clinical practice, product innovation, and changing expectations across care settings. Clinicians are increasingly emphasizing continuity of care and patient-reported outcomes, which has elevated the importance of dosing intervals, injection tolerability, and predictable pharmacodynamics. Simultaneously, manufacturers are pursuing lifecycle strategies that emphasize formulation improvements, novel delivery devices, and expanded label claims to sustain therapeutic relevance.

Another significant shift concerns the integration of digital health and patient support services. Remote monitoring, adherence reminders, and virtual nursing services are complementing pharmacologic therapy to enhance adherence and capture real-world performance data. These services influence payer negotiations and contracting approaches because they demonstrate additional value beyond active pharmaceutical ingredients. Furthermore, the competitive environment is shaped by regulatory pathways that favor robust post-marketing evidence and by an evolving payer landscape that scrutinizes long-term outcomes and cost-effectiveness. Taken together, these forces are redefining how products are developed, launched, and sustained clinically and commercially, reinforcing the need for coordinated strategies across R&D, market access, and stakeholder engagement.

Evaluating the systemic consequences of United States tariff changes in 2025 on supply chains, procurement strategies, and therapeutic access dynamics

Policy shifts in trade and tariffs can have significant downstream implications for how therapies are manufactured, priced, and delivered. In the context of United States tariffs introduced in 2025, supply chain stakeholders faced pressure to reassess sourcing strategies, particularly for high-value active pharmaceutical ingredients and finished-dose manufacturers with cross-border production footprints. Manufacturers responded by diversifying supplier bases, accelerating onshoring initiatives, and engaging contract manufacturers in regions with favorable trade terms to reduce exposure to tariff volatility.

These adaptations influenced procurement strategies among health systems and wholesalers, who sought greater transparency on landed costs and longer-term contracting to stabilize supply. In parallel, payers and integrated delivery networks intensified their scrutiny of total cost of therapy, emphasizing not only acquisition cost but also administration logistics and the impact of adherence on downstream health resource utilization. Importantly, regulatory and procurement teams collaborated to protect continuity of care by prioritizing quality-certified suppliers and contingency stock strategies. While individual organizational responses varied, a common thread was an emphasis on resiliency-ensuring uninterrupted patient access through diversified sourcing, strengthened supplier relationships, and enhanced logistics planning.

In-depth segmentation insights revealing how product type, indication nuance, administration route, distribution pathways, and age cohorts drive differentiated strategic priorities

A nuanced segmentation framework clarifies how differentiated clinical needs and delivery models shape product strategy and commercialization priorities. The product-type dimension highlights distinct therapeutic attributes across Lanreotide Autogel, Octreotide LAR, and Pasireotide LAR, where formulation properties and dosing profiles influence clinician preference and administration workflows. Indication-based differentiation underscores divergent utilization patterns across Acromegaly, Cushing's Disease, and Neuroendocrine Tumors, with Neuroendocrine Tumors further delineated into Gastroenteropancreatic NETs and Pulmonary NETs, each presenting unique diagnostic pathways and multidisciplinary care requirements.

Route-of-administration segmentation contrasts Deep Subcutaneous Injection with Intramuscular Injection, with implications for training requirements, administration setting selection, and patient experience. Distribution channel stratification-spanning Hospital Pharmacies, Mail Order Pharmacies, and Retail Pharmacies-reveals differing inventory models, reimbursement interfaces, and opportunities for value-added services such as home nursing for injections or integrated patient support programs. Finally, patient age group segmentation between Adult and Pediatric populations directs attention to dosing adjustments, safety profiles, and educational needs. Together, these dimensions inform targeted commercial strategies and support the design of tailored clinical programs that address the specific needs of prescribers, patients, and payers in each segment.

Regional landscapes and access considerations across the Americas, Europe Middle East and Africa, and Asia-Pacific that determine clinical uptake and distribution strategies

Regional dynamics influence access, clinical practice norms, and supplier strategies across the global landscape. The Americas continue to exhibit strong integration between specialist centers and large hospital systems, which shapes tendering behavior, distribution logistics, and the structure of patient support services. In these markets, coordinated efforts between payers and providers are central to formulary decisions and to ensuring access for complex chronic conditions.

In the Europe, Middle East & Africa region, heterogeneity in regulatory frameworks and reimbursement mechanisms requires tailored market entry strategies. Multinational manufacturers often need adaptive pricing models and targeted evidence generation plans to meet diverse HTA and reimbursement expectations. Meanwhile, the Asia-Pacific region presents rapidly evolving healthcare infrastructure, with a growing emphasis on improving diagnosis rates and expanding specialty care capacity. Manufacturers seeking traction in Asia-Pacific must balance investments in clinician education, local regulatory engagement, and distribution partnerships to navigate fragmented payer landscapes and to scale access effectively. Across all regions, supply chain resilience, regulatory alignment, and localized patient engagement are critical to sustained uptake.

Competitive and collaboration trends among originators, specialized manufacturers, and service partners that determine long-term positioning in the somatostatin analogue arena

Competitive dynamics in the class are shaped by a mix of established originator companies, specialty manufacturers, and contract development organizations that support formulation and delivery innovation. Leading manufacturers have pursued multifaceted strategies combining life-cycle management, label expansion, and investments in patient services to reinforce product differentiation. Collaboration with clinical networks and key opinion leaders has remained central to driving guideline inclusion and informing real-world evidence programs that substantiate long-term safety and tolerability profiles.

At the same time, third-party manufacturers and specialized injectables partners play an increasingly important role by offering advanced formulation expertise and scalable production capacity. Strategic alliances between originator companies and local distributors or manufacturers help navigate regulatory hurdles and optimize market access in geographies with complex reimbursement environments. Across the competitive landscape, successful players balance R&D investment in improved delivery systems with commercial investments in payer engagement and patient support, recognizing that clinical performance and service offerings together determine long-term clinical adoption and formulary positioning.

Actionable recommendations for leaders to align formulation innovation, supply resilience, and payer engagement to enhance clinical adoption and long-term access

Industry leaders should prioritize strategies that align clinical differentiation with operational resilience and payer-facing value propositions. First, investing in formulation and delivery improvements that reduce administration burden and enhance tolerability will strengthen clinician preference and patient adherence; these improvements should be paired with robust real-world evidence programs to document clinical and humanistic outcomes. Second, diversifying manufacturing and sourcing strategies reduces exposure to trade disruptions and enables more predictable supply, while strategic partnerships with regional CMOs can accelerate local market entry and capacity scaling.

Third, embedding comprehensive patient support services, including injection training, adherence monitoring, and digital reminders, can materially influence persistence and overall treatment value. Fourth, proactive payer engagement that emphasizes total cost of care, outcome-based contracting options, and shared risk arrangements will be increasingly important to secure formulary placement. Finally, targeted investments in pediatric labeling and specialty clinic education expand the addressable clinical base and demonstrate a commitment to clinician and patient needs. By integrating these priorities, leaders can build resilient, differentiated portfolios that respond to clinical expectations and payer demands alike.

Transparent and multi-method research approach combining clinician engagement, regulatory review, and supply chain analysis to ensure robust actionable conclusions

The research methodology combined primary qualitative engagement with quantitative validation to ensure a comprehensive and credible evidence base. Primary inputs included interviews with endocrinologists, neuroendocrine tumor specialists, hospital pharmacists, procurement leaders, and payer representatives to capture frontline perspectives on clinical practice, reimbursement dynamics, and distribution challenges. These engagements were complemented by advisory panels with clinical experts to vet interpretations of real-world care pathways and unmet needs.

Secondary research leveraged peer-reviewed literature, regulatory agency documentation, clinical trial registries, and public filings to map therapeutic mechanisms, safety profiles, and label distinctions among long-acting somatostatin analogues. Supply chain and trade policy analyses drew on customs and trade policy publications and logistics reports to contextualize tariff impacts and sourcing responses. Data synthesis emphasized triangulation across sources, with cross-validation steps to reconcile divergent viewpoints. Throughout the process, analytical rigor was maintained by documenting assumptions, applying sensitivity checks where appropriate, and subjecting key findings to expert review to ensure reproducibility and practical relevance.

Concluding synthesis of clinical opportunities, operational imperatives, and strategic priorities that determine sustained value delivery for somatostatin therapies

The cumulative analysis underscores that long-acting somatostatin analogues occupy an increasingly strategic role in chronic endocrine and neuroendocrine care, driven by clinical demand for sustained biochemical control and by evolving expectations around patient-centered delivery. Innovation in formulations and delivery mechanisms, coupled with enhanced patient support services, creates tangible opportunities to improve adherence and patient experience. Moreover, the broader commercial environment-shaped by regional reimbursement complexity, supply chain vulnerabilities, and payer scrutiny-requires manufacturers to adopt integrated approaches that bridge clinical differentiation and operational resilience.

Looking ahead, stakeholders who align product development with real-world evidence generation, invest in resilient sourcing strategies, and engage payers with data on total clinical value will be best positioned to support clinicians and patients. The interplay between clinical innovation and pragmatic considerations such as distribution channel design and age-specific labeling will determine the pace and breadth of adoption. Ultimately, a coordinated strategy that prioritizes patient outcomes, regulatory compliance, and supply continuity will drive sustainable value for all stakeholders involved in delivering long-acting somatostatin therapies.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Long-acting Somatostatin Analogues Market, by Product Type

  • 8.1. Lanreotide Autogel
  • 8.2. Octreotide LAR
  • 8.3. Pasireotide LAR

9. Long-acting Somatostatin Analogues Market, by Indication

  • 9.1. Acromegaly
  • 9.2. Cushing's Disease
  • 9.3. Neuroendocrine Tumors
    • 9.3.1. Gastroenteropancreatic NETs
    • 9.3.2. Pulmonary NETs

10. Long-acting Somatostatin Analogues Market, by Route Of Administration

  • 10.1. Deep Subcutaneous Injection
  • 10.2. Intramuscular Injection

11. Long-acting Somatostatin Analogues Market, by Distribution Channel

  • 11.1. Hospital Pharmacies
  • 11.2. Mail Order Pharmacies
  • 11.3. Retail Pharmacies

12. Long-acting Somatostatin Analogues Market, by Patient Age Group

  • 12.1. Adult
  • 12.2. Pediatric

13. Long-acting Somatostatin Analogues Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Long-acting Somatostatin Analogues Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Long-acting Somatostatin Analogues Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States Long-acting Somatostatin Analogues Market

17. China Long-acting Somatostatin Analogues Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. Amneal Pharmaceuticals, Inc.
  • 18.6. Bachem Holding AG
  • 18.7. BioSynthema Inc.
  • 18.8. Camurus AB
  • 18.9. Chengdu Tiantaishan Pharmaceutical Co., Ltd.
  • 18.10. Chiasma, Inc.
  • 18.11. Cipla Limited
  • 18.12. Crinetics Pharmaceuticals, Inc.
  • 18.13. Dauntless Pharmaceuticals, Inc.
  • 18.14. Debiopharm Group
  • 18.15. EVER Pharma GmbH
  • 18.16. Ferring Pharmaceuticals
  • 18.17. Ipsen Pharma
  • 18.18. Midatech Pharma PLC
  • 18.19. Mylan N.V.
  • 18.20. Novartis AG
  • 18.21. Peptron Inc.
  • 18.22. Pfizer Inc.
  • 18.23. Recordati S.p.A.
  • 18.24. Sandoz International GmbH
  • 18.25. ScinoPharm Taiwan Ltd.
  • 18.26. Sun Pharmaceutical Industries Ltd.
  • 18.27. Teva Pharmaceutical Industries Ltd.
  • 18.28. Wockhardt Ltd.
  • 18.29. Zydus Lifesciences Limited

LIST OF FIGURES

  • FIGURE 1. GLOBAL LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL LONG-ACTING SOMATOSTATIN ANALOGUES MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY INDICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY PATIENT AGE GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY LANREOTIDE AUTOGEL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY LANREOTIDE AUTOGEL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY LANREOTIDE AUTOGEL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY OCTREOTIDE LAR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY OCTREOTIDE LAR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY OCTREOTIDE LAR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY PASIREOTIDE LAR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY PASIREOTIDE LAR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY PASIREOTIDE LAR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY ACROMEGALY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY ACROMEGALY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY ACROMEGALY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY CUSHING'S DISEASE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY CUSHING'S DISEASE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY CUSHING'S DISEASE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY NEUROENDOCRINE TUMORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY NEUROENDOCRINE TUMORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY NEUROENDOCRINE TUMORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY NEUROENDOCRINE TUMORS, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY GASTROENTEROPANCREATIC NETS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY GASTROENTEROPANCREATIC NETS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY GASTROENTEROPANCREATIC NETS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY PULMONARY NETS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY PULMONARY NETS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY PULMONARY NETS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY DEEP SUBCUTANEOUS INJECTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY DEEP SUBCUTANEOUS INJECTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY DEEP SUBCUTANEOUS INJECTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY INTRAMUSCULAR INJECTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY INTRAMUSCULAR INJECTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY INTRAMUSCULAR INJECTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY MAIL ORDER PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY MAIL ORDER PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY MAIL ORDER PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY ADULT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY ADULT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY ADULT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY PEDIATRIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY PEDIATRIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. AMERICAS LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 55. AMERICAS LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 56. AMERICAS LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 57. AMERICAS LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY NEUROENDOCRINE TUMORS, 2018-2032 (USD MILLION)
  • TABLE 58. AMERICAS LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 59. AMERICAS LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 60. AMERICAS LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. NORTH AMERICA LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. NORTH AMERICA LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 63. NORTH AMERICA LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 64. NORTH AMERICA LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY NEUROENDOCRINE TUMORS, 2018-2032 (USD MILLION)
  • TABLE 65. NORTH AMERICA LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 66. NORTH AMERICA LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 67. NORTH AMERICA LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 68. LATIN AMERICA LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 69. LATIN AMERICA LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 70. LATIN AMERICA LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 71. LATIN AMERICA LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY NEUROENDOCRINE TUMORS, 2018-2032 (USD MILLION)
  • TABLE 72. LATIN AMERICA LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 73. LATIN AMERICA LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 74. LATIN AMERICA LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 75. EUROPE, MIDDLE EAST & AFRICA LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 76. EUROPE, MIDDLE EAST & AFRICA LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 77. EUROPE, MIDDLE EAST & AFRICA LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 78. EUROPE, MIDDLE EAST & AFRICA LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY NEUROENDOCRINE TUMORS, 2018-2032 (USD MILLION)
  • TABLE 79. EUROPE, MIDDLE EAST & AFRICA LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 80. EUROPE, MIDDLE EAST & AFRICA LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 81. EUROPE, MIDDLE EAST & AFRICA LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 82. EUROPE LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 83. EUROPE LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 84. EUROPE LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 85. EUROPE LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY NEUROENDOCRINE TUMORS, 2018-2032 (USD MILLION)
  • TABLE 86. EUROPE LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 87. EUROPE LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 88. EUROPE LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 89. MIDDLE EAST LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 90. MIDDLE EAST LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 91. MIDDLE EAST LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 92. MIDDLE EAST LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY NEUROENDOCRINE TUMORS, 2018-2032 (USD MILLION)
  • TABLE 93. MIDDLE EAST LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 94. MIDDLE EAST LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 95. MIDDLE EAST LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 96. AFRICA LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 97. AFRICA LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 98. AFRICA LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 99. AFRICA LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY NEUROENDOCRINE TUMORS, 2018-2032 (USD MILLION)
  • TABLE 100. AFRICA LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 101. AFRICA LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 102. AFRICA LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 103. ASIA-PACIFIC LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 104. ASIA-PACIFIC LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 105. ASIA-PACIFIC LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 106. ASIA-PACIFIC LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY NEUROENDOCRINE TUMORS, 2018-2032 (USD MILLION)
  • TABLE 107. ASIA-PACIFIC LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 108. ASIA-PACIFIC LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 109. ASIA-PACIFIC LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 111. ASEAN LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 112. ASEAN LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 113. ASEAN LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 114. ASEAN LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY NEUROENDOCRINE TUMORS, 2018-2032 (USD MILLION)
  • TABLE 115. ASEAN LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 116. ASEAN LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 117. ASEAN LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 118. GCC LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 119. GCC LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 120. GCC LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 121. GCC LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY NEUROENDOCRINE TUMORS, 2018-2032 (USD MILLION)
  • TABLE 122. GCC LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 123. GCC LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 124. GCC LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 125. EUROPEAN UNION LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 126. EUROPEAN UNION LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 127. EUROPEAN UNION LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 128. EUROPEAN UNION LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY NEUROENDOCRINE TUMORS, 2018-2032 (USD MILLION)
  • TABLE 129. EUROPEAN UNION LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 130. EUROPEAN UNION LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 131. EUROPEAN UNION LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 132. BRICS LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 133. BRICS LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 134. BRICS LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 135. BRICS LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY NEUROENDOCRINE TUMORS, 2018-2032 (USD MILLION)
  • TABLE 136. BRICS LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 137. BRICS LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 138. BRICS LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 139. G7 LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 140. G7 LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 141. G7 LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 142. G7 LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY NEUROENDOCRINE TUMORS, 2018-2032 (USD MILLION)
  • TABLE 143. G7 LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 144. G7 LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 145. G7 LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 146. NATO LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 147. NATO LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 148. NATO LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 149. NATO LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY NEUROENDOCRINE TUMORS, 2018-2032 (USD MILLION)
  • TABLE 150. NATO LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 151. NATO LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 152. NATO LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 153. GLOBAL LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 154. UNITED STATES LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 155. UNITED STATES LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 156. UNITED STATES LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 157. UNITED STATES LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY NEUROENDOCRINE TUMORS, 2018-2032 (USD MILLION)
  • TABLE 158. UNITED STATES LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 159. UNITED STATES LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 160. UNITED STATES LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 161. CHINA LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 162. CHINA LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 163. CHINA LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 164. CHINA LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY NEUROENDOCRINE TUMORS, 2018-2032 (USD MILLION)
  • TABLE 165. CHINA LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 166. CHINA LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 167. CHINA LONG-ACTING SOMATOSTATIN ANALOGUES MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)